home > news > detailed info

PCI Pharma Services Announces Organization Updates

PCI Pharma Services

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.

The senior positions include newly created and expanded roles in Strategic Marketing, Program Management, Clinical Services and Global Clinical Quality.

Commenting on the changes, PCI Chief Executive Officer Salim Haffar said: “The strategic direction PCI is taking will help us and our clients prepare for the future. We are investing in global infrastructure, innovation, and our leadership to ensure enhanced focus on delivering the best customer experience and solidifying our well-recognized position within the industry. I’m inspired by the strength of our internal management team, and our ability to elevate and leverage their talent to launch these new functions and initiatives.”

• To support the continued growth and strength of PCI’s Clinical Services business, Tim Roberts has been promoted to the position of Vice President, Global Sales, Clinical Services. With a 22-year career in clinical packaging, Tim has been successfully leading and building PCI’s US Clinical Sales Team for the last four years, and before this led its UK Clinical Operations. He has made a significant and positive impact on team members, Clinical business results and most importantly PCI’s client base. Prior to joining PCI, Tim delivered strong results at Catalent and Aptuit in sales, program management and operations leadership roles.

• In a key role in Quality, Tris Evans has been promoted to the position of Vice President, Global Quality, Clinical Services, and will lead the Clinical Quality Directors and teams at PCI’s Rockford, San Diego, Bridgend, Dublin and Hay sites. In Tris’ 11 years with PCI, he has been very successful in leading and building a well-recognized Global Clinical Quality team, ensuring harmonization of Clinical Quality standards globally, supporting key activities and business drivers and delighting PCI’s customers. Previously, Tris worked at Norgine and Penn Pharma in roles of increasing responsibility in Quality.

• Driving alignment and consistency for PCI’s Commercial clients, Justin Schroeder has been promoted to the newly created role of Vice President, Global Program Management; a position designed to secure PCI’s reputation of providing the best customer experience in our industry through the program management team. Justin is well placed for this role; during his 19-year history with PCI, he has served in numerous executive, client-facing roles including packaging design, program management, and marketing. During his tenure, he has built world-class teams which have differentiated PCI as a technology leader and driven year over year revenue growth.

• As PCI prepares to increase its presence worldwide, Sue Ritchie has been promoted to the role of Senior Director, Global Marketing. The purpose and scope of this new role is to expand PCI’s brand awareness and impact across the globe, leveraging external and internal resources to continue to drive innovation and recognition. Sue has most recently served in a Business Development role with PCI, increasing sales and relationships for its Manufacturing business. Prior to PCI, Sue held numerous senior level marketing positions at Delavau, Johnson and Johnson, Pfizer and GE Healthcare. She has a strong track record of marketing intelligence, strategy and execution and will bring that knowledge to PCI in her new role.

For further information about PCI’s expertise, please visit here.

About PCI
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives.

For more information, please visit or follow us on Twitter at @PCI_Social.

Tom Gosschalk / Carrie Lowe at BECG
T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
Print this page
Send to a friend
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement